BRAF and central nervous system cancer: These results mirror recent findings in IDH-mutant glioma where IDH mutation is present universally, independent of grade or recurrence, whereas non-IDH mutant gliomas showed strikingly different mutational patterns at recurrence including growth regulatory gene mutations such as BRAF V600E [33].